Basic Research and Clinical Aspects of Adamantinomatous Craniopharyngioma
Author | : Juan Pedro Martinez-Barbera |
Publisher | : Springer |
Total Pages | : 223 |
Release | : 2017-04-19 |
ISBN-10 | : 9783319518909 |
ISBN-13 | : 3319518909 |
Rating | : 4/5 (909 Downloads) |
Download or read book Basic Research and Clinical Aspects of Adamantinomatous Craniopharyngioma written by Juan Pedro Martinez-Barbera and published by Springer. This book was released on 2017-04-19 with total page 223 pages. Available in PDF, EPUB and Kindle. Book excerpt: This astute volume brings together the latest expert research on adamantinomatous craniopharyngiomas (ACPs). ACPs are histologically benign but clinically aggressive tumors exhibiting a high propensity for local invasion into the hypothalamus, optic and vascular structures. These tumors, as well as the current treatments, may result in pan-hypopituitarism, diabetes insipidus, morbid obesity followed by type II diabetes mellitus, blindness, as well as serious behavioral and psychosocial impairments. Exploring in detail advances in both the understanding of tumor biology as well as clinical advances in patient management are explored in detail, this book will also look towards potential new treatment approaches. Basic Research and Clinical Aspects of Adamantinomatous Craniopharyngioma is the first book compiling all current research on ACPs. Mouse and human studies have unequivocally demonstrated that mutations in CTNNB1 encoding -catenin underlie the etiology of the majority, if not all ACP tumors. Genetic studies in mice have shown that ACPs are tumors of the pituitary gland and not of the hypothalamus as previously thought, and are derived from Rathke’s pouch precursors. In addition, a role for tissue-specific adult pituitary stem cells has been revealed as causative of ACP. Together, these studies have provided novel insights into the molecular and cellular etiology as well as the pathogenesis of human ACP. Finally, this volume covers new treatment approaches that have been shown to be effective both in reducing ACP burden as well as reducing the morbidity associated with therapy.